Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following: * Recurrent ovarian, fallopian tube, or peritoneal cavity cancer * Metastatic breast cancer * Advanced endometrial cancer * Planning to receive chemotherapy with doxorubicin HCl liposome at a dose of 40 mg/m\^2 * Hormone receptor status: * Not specified PATIENT CHARACTERISTICS: Sex * Not specified Menopausal status: * Not specified Performance status * Karnofsky 60-100% Life expectancy * Not specified Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9.0 g/dL Hepatic * AST and ALT ≤ 2 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 2 times ULN * Bilirubin normal Renal * Creatinine ≤ 2.0 mg/dL Cardiovascular * Ejection fraction ≥ 50% by MUGA or 2-D echocardiogram * No history of cardiac disease * No New York Heart Association class II-IV heart disease * No clinical evidence of congestive heart failure Other * Not pregnant or nursing * Fertile patients must use effective contraception during and for 3 months after completion of study treatment * No active infection requiring antibiotics * No history of hypersensitivity reaction attributed to a conventional formulation of doxorubicin HCl or doxorubicin HCl liposome and any of its components * No other invasive malignancy within the past 5 years except nonmelanoma or basal cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy * At least 3 weeks since prior biologic or …